Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase EARLY_PHASE1 1Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 182Triple Negative Breast Neoplasms 24Lung Neoplasms 16Ovarian Neoplasms 11Melanoma 11Prostatic Neoplasms 10Pancreatic Neoplasms 10Colonic Neoplasms 10Sarcoma 9Neoplasms 8Stomach Neoplasms 7Carcinoma, Intraductal, Noninfiltrating 7Head and Neck Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Breast Neoplasms, Male 5Uterine Cervical Neoplasms 4Glioblastoma 4Carcinoma, Ductal, Breast 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Liver Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3Carcinoma, Lobular 3Carcinoma, Hepatocellular 3Rectal Neoplasms 2

Interventions

gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Fibroadenoma × Breast × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡